Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 92 articles: HTML format

Single Articles

August 2020
1. MELOSKY B, Cheema PK, Brade A, McLeod D, et al
   Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
   Oncologist. 2020 Aug 29. doi: 10.1634/theoncologist.2020-0193.
   PubMed     Abstract available
   
   
   July 2020
2. NOSAKI K, Yamanaka T, Hamada A, Shiraishi Y, et al
   Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
   Oncologist. 2020 Jul 12. doi: 10.1634/theoncologist.2020-0640.
   PubMed     Abstract available
   
   
   
3. JOHN A, Shah RA, Wong WB, Schneider CE, et al
   Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated With the Use of Companion Diagnostics.
   Oncologist. 2020 Jul 6. doi: 10.1634/theoncologist.2019-0864.
   PubMed     Abstract available
   
   
   
4. MILBURY K, Li Y, Durrani S, Liao Z, et al
   A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and their Spouses: Results of a 3-Arm Pilot Randomized Controlled Trial.
   Oncologist. 2020 Jul 4. doi: 10.1634/theoncologist.2020-0125.
   PubMed     Abstract available
   
   
   June 2020
5. NAKAMURA A, Tanaka H, Saito R, Suzuki A, et al
   Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
   Oncologist. 2020 Jun 19. doi: 10.1634/theoncologist.2020-0545.
   PubMed     Abstract available
   
   
   
6. ITCHINS M, Lau B, Hudson AL, Westman H, et al
   ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
   Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0075.
   PubMed     Abstract available
   
   
   
7. BONANNO L, Pavan A, Ferro A, Calvetti L, et al
   Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
   Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0148.
   PubMed     Abstract available
   
   
   
8. YU Z, Xu Z, He Z, Lai J, et al
   Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
   Oncologist. 2020 Jun 13. doi: 10.1634/theoncologist.2020-0519.
   PubMed     Abstract available
   
   
   
9. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
   Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
   Oncologist. 2020 Jun 3. doi: 10.1634/theoncologist.2020-0011.
   PubMed     Abstract available
   
   
   May 2020
10. TAKAYAMA K, Takeshita M, Inoue K, Ichiki M, et al
    Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
    Oncologist. 2020 May 9. doi: 10.1634/theoncologist.2020-0322.
    PubMed     Abstract available
    
    
    April 2020
11. CHOI H, Pennell NA
    Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening.
    Oncologist. 2020 Apr 9. doi: 10.1634/theoncologist.2020-0149.
    PubMed    
    
    
    
12. LIU Y, Hu X, Jiang J, Yang L, et al
    A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
    Oncologist. 2020 Apr 6. doi: 10.1634/theoncologist.2019-0391.
    PubMed     Abstract available
    
    
    
13. AKAMATSU H, Murakami E, Oyanagi J, Shibaki R, et al
    Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:e679-e683.
    PubMed     Abstract available
    
    
    
14. IWAMA E, Goto Y, Murakami H, Tsumura S, et al
    Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
    Oncologist. 2020;25:306-e618.
    PubMed     Abstract available
    
    
    March 2020
15. POPAT V, Lu R, Ahmed M, Park JY, et al
    Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Oncologist. 2020 Mar 31. doi: 10.1634/theoncologist.2019-0814.
    PubMed     Abstract available
    
    
    
16. MA Y, Fang W, Zhang Y, Yang Y, et al
    KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer.
    Oncologist. 2020 Mar 5. doi: 10.1634/theoncologist.2020-0067.
    PubMed     Abstract available
    
    
    
17. CUFER T, Ciuleanu TE, Berzinec P, Galffy G, et al
    Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
    Oncologist. 2020;25:e598-e601.
    PubMed     Abstract available
    
    
    
18. TAKAYAMA K, Ichiki M, Matsumoto T, Ebi N, et al
    Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:208-e417.
    PubMed     Abstract available
    
    
    
19. AVANCINI A, Sartori G, Gkountakos A, Casali M, et al
    Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
    Oncologist. 2020;25:e555-e569.
    PubMed     Abstract available
    
    
    
20. ASO M, Toi Y, Sugisaka J, Aiba T, et al
    Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:e536-e544.
    PubMed     Abstract available
    
    
    February 2020
21. JIANG S, Liang H, Liu Z, Zhao S, et al
    The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
    Oncologist. 2020 Feb 20. doi: 10.1634/theoncologist.2019-0838.
    PubMed     Abstract available
    
    
    
22. PATEL SP, Pakkala S, Pennell NA, Reckamp KL, et al
    Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
    Oncologist. 2020 Feb 12. doi: 10.1634/theoncologist.2020-0034.
    PubMed     Abstract available
    
    
    January 2020
23. BEHERA M, Steuer CE, Liu Y, Fernandez F, et al
    Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
    Oncologist. 2020 Jan 14. doi: 10.1634/theoncologist.2019-0661.
    PubMed     Abstract available
    
    
    November 2019
24. CUFER T, Ciuleanu TE, Berzinec P, Galffy G, et al
    Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
    Oncologist. 2019 Nov 29. pii: theoncologist.2019-0523.
    PubMed     Abstract available
    
    
    
25. RAGHAVAN D, Wheeler M, Doege D, Doty JD 2nd, et al
    Initial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations.
    Oncologist. 2019 Nov 26. pii: theoncologist.2019-0802.
    PubMed     Abstract available
    
    
    
26. AVANCINI A, Sartori G, Gkountakos A, Casali M, et al
    Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
    Oncologist. 2019 Nov 26. pii: theoncologist.2019-0463.
    PubMed     Abstract available
    
    
    
27. AKAMATSU H, Murakami E, Oyanagi J, Shibaki R, et al
    Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Nov 19. pii: theoncologist.2019-0299.
    PubMed     Abstract available
    
    
    
28. ASO M, Toi Y, Sugisaka J, Aiba T, et al
    Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Nov 7. pii: theoncologist.2019-0550.
    PubMed     Abstract available
    
    
    October 2019
29. IWAMA E, Goto Y, Murakami H, Tsumura S, et al
    Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
    Oncologist. 2019 Oct 30. pii: theoncologist.2019-0728.
    PubMed     Abstract available
    
    
    
30. TSUCHIYA-KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
    Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Oct 24. pii: theoncologist.2019-0746.
    PubMed     Abstract available
    
    
    
31. TAKAYAMA K, Ichiki M, Matsumoto T, Ebi N, et al
    Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Oct 21. pii: theoncologist.2019-0717.
    PubMed     Abstract available
    
    
    September 2019
32. CHEN Y, Criss SD, Watson TR, Eckel A, et al
    Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States.
    Oncologist. 2019 Sep 9. pii: theoncologist.2019-0303.
    PubMed     Abstract available
    
    
    August 2019
33. SPIGEL DR, Shipley DL, Waterhouse DM, Jones SF, et al
    A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
    Oncologist. 2019 Aug 16. pii: theoncologist.2018-0518.
    PubMed     Abstract available
    
    
    July 2019
34. TAKAYAMA K, Ichiki M, Tokunaga S, Inoue K, et al
    Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Jul 22. pii: theoncologist.2019-0513.
    PubMed     Abstract available
    
    
    May 2019
35. FINTELMANN FJ, Troschel FM, Kuklinski MW, McDermott S, et al
    Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.
    Oncologist. 2019 May 31. pii: theoncologist.2019-0158.
    PubMed     Abstract available
    
    
    
36. MELOSKY B, Juergens R, Hirsh V, McLeod D, et al
    Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
    Oncologist. 2019 May 28. pii: theoncologist.2019-0027.
    PubMed     Abstract available
    
    
    
37. LEE JH, Chen HY, Hsu FM, Chen JS, et al
    Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
    Oncologist. 2019 May 24. pii: theoncologist.2019-0152.
    PubMed     Abstract available
    
    
    
38. FURUTA M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, et al
    Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Oncologist. 2019 May 8. pii: theoncologist.2018-0676.
    PubMed     Abstract available
    
    
    April 2019
39. ZHENG L, Wang Y, Xu Z, Yang Q, et al
    Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Oncologist. 2019 Apr 30. pii: theoncologist.2019-0285.
    PubMed     Abstract available
    
    
    
40. CHIHARA Y, Yoshimura A, Date K, Takemura Y, et al
    Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Oncologist. 2019 Apr 30. pii: theoncologist.2019-0290.
    PubMed     Abstract available
    
    
    
41. DUMA N, Abdel-Ghani A, Yadav S, Hoversten KP, et al
    Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
    Oncologist. 2019 Apr 29. pii: theoncologist.2019-0094.
    PubMed     Abstract available
    
    
    
42. RYU JS, Lim JH, Lee MK, Lee SJ, et al
    Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis.
    Oncologist. 2019 Apr 29. pii: theoncologist.2019-0147.
    PubMed     Abstract available
    
    
    
43. OTSUBO K, Sakai K, Takeshita M, Harada D, et al
    Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Oncologist. 2019 Apr 25. pii: theoncologist.2019-0101.
    PubMed     Abstract available
    
    
    
44. PAVAN A, Calvetti L, Dal Maso A, Attili I, et al
    Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Oncologist. 2019 Apr 23. pii: theoncologist.2018-0563.
    PubMed     Abstract available
    
    
    
45. ZHANG C, Sun X, Dang K, Li K, et al
    Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network.
    Oncologist. 2019 Apr 17. pii: theoncologist.2018-0908.
    PubMed     Abstract available
    
    
    
46. CRINO L, Bidoli P, Delmonte A, Grossi F, et al
    Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
    Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737.
    PubMed     Abstract available
    
    
    
47. SEQUIST LV, Gray JE, Harb WA, Lopez-Chavez A, et al
    Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695.
    PubMed     Abstract available
    
    
    March 2019
48. ABDEL KARIM N, Kelly K
    Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
    Oncologist. 2019 Mar 26. pii: theoncologist.2018-0112.
    PubMed     Abstract available
    
    
    
49. WEN S, Dai L, Wang L, Wang W, et al
    Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Oncologist. 2019 Mar 22. pii: theoncologist.2018-0572.
    PubMed     Abstract available
    
    
    
50. CHAE YK, Davis AA, Agte S, Pan A, et al
    Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Oncologist. 2019 Mar 13. pii: theoncologist.2018-0433.
    PubMed     Abstract available
    
    
    
51. PASELLO G, Vicario G, Zustovich F, Oniga F, et al
    From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
    Oncologist. 2019 Mar 7. pii: theoncologist.2018-0712.
    PubMed     Abstract available
    
    
    February 2019
52. SONBOL MB, Halling KC, Douglas DD, Ross HJ, et al
    A Case of Donor-Transmitted Non-Small Cell Lung Cancer After Liver Transplantation: An Unwelcome Guest.
    Oncologist. 2019 Feb 12. pii: theoncologist.2018-0517.
    PubMed     Abstract available
    
    
    
53. XIA L, Liu Y, Wang Y
    PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Oncologist. 2019;24.
    PubMed     Abstract available
    
    
    
54. LU S, Yu Y, Yang Y
    Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
    Oncologist. 2019;24.
    PubMed     Abstract available
    
    
    January 2019
55. PARK H, Dahlberg SE, Lydon CA, Araki T, et al
    M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
    Oncologist. 2019 Jan 29. pii: theoncologist.2018-0596.
    PubMed     Abstract available
    
    
    
56. NAKAO A, Hiranuma O, Uchino J, Sakaguchi C, et al
    Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Oncologist. 2019 Jan 16. pii: theoncologist.2019-0003.
    PubMed     Abstract available
    
    
    
57. PATIL PD, Shapiro M, Hashemi Sadraei N, Pennell NA, et al
    An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2019 Jan 2. pii: theoncologist.2018-0857.
    PubMed     Abstract available
    
    
    December 2018
58. CHALMERS A, Cannon L, Akerley W
    Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
    Oncologist. 2018 Dec 31. pii: theoncologist.2018-0296.
    PubMed     Abstract available
    
    
    
59. KHOZIN S, Carson KR, Zhi J, Tucker M, et al
    Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Oncologist. 2018 Dec 27. pii: theoncologist.2018-0307.
    PubMed     Abstract available
    
    
    
60. YOSHIMURA A, Chihara Y, Date K, Tamiya N, et al
    A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2018 Dec 21. pii: theoncologist.2018-0858.
    PubMed     Abstract available
    
    
    September 2018
61. WU B, Gu X, Zhang Q, Xie F, et al
    Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
    Oncologist. 2018 Sep 26. pii: theoncologist.2018-0150.
    PubMed     Abstract available
    
    
    August 2018
62. XIONG L, Li R, Sun J, Lou Y, et al
    Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
    Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120.
    PubMed     Abstract available
    
    
    
63. BUTTIGLIERO C, Shepherd FA, Barlesi F, Schwartz B, et al
    Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089.
    PubMed     Abstract available
    
    
    
64. XIE L, Nagpal S, Wakelee HA, Li G, et al
    Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
    Oncologist. 2018 Aug 20. pii: theoncologist.2018-0264.
    PubMed     Abstract available
    
    
    
65. SATO T, Soejima K, Fujisawa D, Takeuchi M, et al
    Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.
    Oncologist. 2018 Aug 17. pii: theoncologist.2017-0329.
    PubMed     Abstract available
    
    
    
66. RYSKA A, Buiga R, Fakirova A, Kern I, et al
    Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
    Oncologist. 2018 Aug 3. pii: theoncologist.2018-0008.
    PubMed     Abstract available
    
    
    
67. GREGORC V, Cavina R, Novello S, Grossi F, et al
    NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
    Oncologist. 2018 Aug 3. pii: theoncologist.2018-0292.
    PubMed     Abstract available
    
    
    
68. KAMATH SD, Kumthekar PU, Kruser TJ, Mohindra NA, et al
    Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.
    Oncologist. 2018 Aug 2. pii: theoncologist.2018-0022.
    PubMed     Abstract available
    
    
    June 2018
69. TOI Y, Sugawara S, Kawashima Y, Aiba T, et al
    Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Oncologist. 2018 Jun 22. pii: theoncologist.2017-0384.
    PubMed     Abstract available
    
    
    April 2018
70. CHABNER BA, Nabel CS
    Canakinumab and Lung Cancer: Intriguing, but Is It Real?
    Oncologist. 2018 Apr 17. pii: theoncologist.2018-0116.
    PubMed    
    
    
    
71. LABABEDE O, Meziane MA
    The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0659.
    PubMed     Abstract available
    
    
    
72. CHU CY, Choi J, Eaby-Sandy B, Langer CJ, et al
    Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0582.
    PubMed     Abstract available
    
    
    
73. AHLUWALIA MS, Becker K, Levy BP
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0572.
    PubMed     Abstract available
    
    
    March 2018
74. SAROCCHI M, Grossi F, Arboscello E, Bellodi A, et al
    Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Oncologist. 2018 Mar 22. pii: theoncologist.2017-0452.
    PubMed     Abstract available
    
    
    
75. SUH JH, Schrock AB, Johnson A, Lipson D, et al
    Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493.
    PubMed     Abstract available
    
    
    February 2018
76. MARRONE KA, Zhou X, Forde PM, Purtell M, et al
    A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465.
    PubMed     Abstract available
    
    
    
77. VON PAWEL J, Spigel DR, Ervin T, Losonczy G, et al
    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 7. pii: theoncologist.2017-0690.
    PubMed     Abstract available
    
    
    January 2018
78. KHOZIN S, Abernethy AP, Nussbaum NC, Zhi J, et al
    Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Oncologist. 2018 Jan 9. pii: theoncologist.2017-0353.
    PubMed     Abstract available
    
    
    December 2017
79. ODOGWU L, Mathieu L, Goldberg KB, Blumenthal GM, et al
    FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Oncologist. 2017 Dec 14. pii: theoncologist.2017-0425.
    PubMed     Abstract available
    
    
    
80. OGAWA A, Kondo K, Takei H, Fujisawa D, et al
    Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer.
    Oncologist. 2017 Dec 6. pii: theoncologist.2017-0187.
    PubMed     Abstract available
    
    
    September 2017
81. KUDERER NM, Poniewierski MS, Culakova E, Lyman GH, et al
    Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Oncologist. 2017 Sep 26. pii: theoncologist.2017-0205.
    PubMed     Abstract available
    
    
    August 2017
82. PAI-SCHERF L, Blumenthal GM, Li H, Subramaniam S, et al
    FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Oncologist. 2017 Aug 23. pii: theoncologist.2017-0078.
    PubMed     Abstract available
    
    
    
83. STINCHCOMBE TE
    Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2017 Aug 4. pii: theoncologist.2017-0204.
    PubMed     Abstract available
    
    
    July 2017
84. HAN Y, Zhang R, Lin G, Zhang K, et al
    Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.
    Oncologist. 2017 Jul 12. pii: theoncologist.2017-0042.
    PubMed     Abstract available
    
    
    May 2017
85. SCILLA KA, Bentzen SM, Lam VK, Mohindra P, et al
    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Oncologist. 2017 May 22. pii: theoncologist.2016-0443.
    PubMed     Abstract available
    
    
    
86. MIYAUCHI E, Inoue A, Usui K, Sugawara S, et al
    Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Oncologist. 2017 May 19. pii: theoncologist.2017-0059.
    PubMed     Abstract available
    
    
    
87. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Oncologist. 2017 May 15. pii: theoncologist.2016-0331.
    PubMed     Abstract available
    
    
    
88. BAIK CS, Myall NJ, Wakelee HA
    Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
    Oncologist. 2017 May 9. pii: theoncologist.2016-0458.
    PubMed     Abstract available
    
    
    April 2017
89. AGGARWAL C, Borghaei H
    Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    Oncologist. 2017 Apr 13. pii: theoncologist.2016-0345.
    PubMed     Abstract available
    
    
    
90. NISHIJIMA TF, Shachar SS, Nyrop KA, Muss HB, et al
    Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Oncologist. 2017;22:470-479.
    PubMed     Abstract available
    
    
    February 2017
91. WANG X, Wang X, Hodgson L, George SL, et al
    Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Oncologist. 2017;22:189-198.
    PubMed     Abstract available
    
    
    January 2017
92. BARSANTI-INNES B, Hey SP, Kimmelman J
    The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
    Oncologist. 2017;22:89-96.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: